GCG and diabetes mellitus: This was supported by pooled analysis of trials of GLP-1 agonists in HFpEF from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials, which showed that semaglutide significantly improved clinical symptoms, physical limitations, and 6 min walk distance [138].